HRP20211007T1 - Prevencija ili liječenje uratne bolesti ili gihta - Google Patents
Prevencija ili liječenje uratne bolesti ili gihta Download PDFInfo
- Publication number
- HRP20211007T1 HRP20211007T1 HRP20211007TT HRP20211007T HRP20211007T1 HR P20211007 T1 HRP20211007 T1 HR P20211007T1 HR P20211007T T HRP20211007T T HR P20211007TT HR P20211007 T HRP20211007 T HR P20211007T HR P20211007 T1 HRP20211007 T1 HR P20211007T1
- Authority
- HR
- Croatia
- Prior art keywords
- dione
- purine
- dihydro
- chloro
- compound
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 11
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims 10
- 201000005569 Gout Diseases 0.000 title claims 8
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims 7
- 229940116269 uric acid Drugs 0.000 title claims 7
- 230000002265 prevention Effects 0.000 title claims 3
- 150000001875 compounds Chemical class 0.000 claims 26
- 150000003839 salts Chemical class 0.000 claims 20
- 239000012453 solvate Substances 0.000 claims 20
- 239000000825 pharmaceutical preparation Substances 0.000 claims 17
- 201000010099 disease Diseases 0.000 claims 7
- CGAMDQCXAAOFSR-UHFFFAOYSA-N 8-chloro-3-pentyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(CCCCC)C2=C1NC(Cl)=N2 CGAMDQCXAAOFSR-UHFFFAOYSA-N 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- 201000001431 Hyperuricemia Diseases 0.000 claims 4
- IXKIATZUIFUKIE-UHFFFAOYSA-N 3-butyl-8-chloro-1-methyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(CCCC)C2=C1NC(Cl)=N2 IXKIATZUIFUKIE-UHFFFAOYSA-N 0.000 claims 3
- IWPBNHSYRXVLEI-UHFFFAOYSA-N 3-butyl-8-chloro-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(CCCC)C2=C1NC(Cl)=N2 IWPBNHSYRXVLEI-UHFFFAOYSA-N 0.000 claims 3
- IQAOHTRPZVQICW-UHFFFAOYSA-N 8-chloro-1-methyl-3-(3-methylbutyl)-7H-purine-2,6-dione Chemical compound ClC1=NC=2N(C(N(C(C=2N1)=O)C)=O)CCC(C)C IQAOHTRPZVQICW-UHFFFAOYSA-N 0.000 claims 3
- IRKQPAMTLHYJDE-UHFFFAOYSA-N 8-chloro-1-methyl-3-pentyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(CCCCC)C2=C1NC(Cl)=N2 IRKQPAMTLHYJDE-UHFFFAOYSA-N 0.000 claims 3
- GCRUYCXLSLIMAO-UHFFFAOYSA-N 8-chloro-3-(2-methylpropyl)-7H-purine-2,6-dione Chemical compound ClC1=NC=2N(C(NC(C=2N1)=O)=O)CC(C)C GCRUYCXLSLIMAO-UHFFFAOYSA-N 0.000 claims 3
- NCLSUDNPUAQNGG-UHFFFAOYSA-N 8-chloro-3-(3-methylbutyl)-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(CCC(C)C)C2=C1NC(Cl)=N2 NCLSUDNPUAQNGG-UHFFFAOYSA-N 0.000 claims 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- 206010046337 Urate nephropathy Diseases 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 229910052801 chlorine Chemical group 0.000 claims 3
- 239000000460 chlorine Chemical group 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 3
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000018937 joint inflammation Diseases 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 206010007027 Calculus urinary Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 201000001509 acute urate nephropathy Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000019808 uric acid nephrolithiasis Diseases 0.000 claims 1
- 208000008281 urolithiasis Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (17)
1. Spoj, naznačen time, da je predstavljen formulom (I), ili njegova farmaceutski prihvatljiva sol ili njegov solvat, ili farmaceutski pripravak, naznačen time, da sadrži spoj predstavljen formulom (I), ili njegovu farmaceutski prihvatljivu sol ili njegov solvat za uporabu u prevenciji ili liječenju bolesti povezanih s povišenjem nivoa mokraćne kiseline u organizmu,
[image]
u kojoj
R1 predstavlja vodik ili metil,
R2 predstavlja etil, propil, 2-metilpropil, butil, 3-metilbutil ili pentil, i
R3 predstavlja fluor ili klor.
2. Spoj ili njegova farmaceutski prihvatljiva sol ili njegov solvat, ili farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da se spoj bira iz skupine koja se sastoji od:
8-kloro-3-pentil-3,7-dihidro-1H-purin-2,6-dion,
8-kloro-3-butil-3,7-dihidro-1H-purin-2,6-dion,
8-kloro-1-metil-3-butil-3,7-dihidro-1H-purin-2,6-dion,
8-kloro-1-metil-3-pentil-3,7-dihidro-1H-purin-2,6-dion,
8-kloro-3-(3-metilbutil)-3,7-dihidro-1H-purin-2,6-dion,
8-kloro-3-(2-metilpropil)-3,7-dihidro-1H-purin-2,6-dion, i
8-kloro-1-metil-3-(3-metilbutil)-3,7-dihidro-1H-purin-2,6-dion.
3. Spoj ili njegova farmaceutski prihvatljiva sol ili njegov solvat, ili farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, da spoj jest 8-kloro-3-pentil-3,7-dihidro-1H-purin-2,6-dion ili njegov hidrat.
4. Spoj ili njegova farmaceutski prihvatljiva sol ili njegov solvat, ili farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da se kod bolesti povezanih s povišenjem nivoa mokraćne kiseline u organizmu radi o uratnoj bolesti i/ili o bolesti gihta (ulozi).
5. Spoj, naznačen time, da je predstavljen formulom (I), ili njegova farmaceutski prihvatljiva sol ili njegov solvat, ili farmaceutski pripravak, naznačen time, da sadrži spoj predstavljen formulom (I), ili njegovu farmaceutski prihvatljivu sol ili njegov solvat za uporabu u prevenciji ili liječenju bolesti povezanih s povišenjem nivoa mokraćne kiseline u organizmu, pri čemu se kod bolesti povezanih s povišenjem nivoa mokraćne kiseline radi o uratnoj bolesti i/ili bolesti gihta (ulozi);
[image]
gdje s R1 bira iz skupine koju čine vodik i C1-4 alkil, pri čemu je navedeni
C1-4 alkil nesupstituiran ili je opcionalno supstituiran s jednim ili više halogena, cijano, CF3 ili njihovim kombinacijama;
R2 se bira iz skupine koju čine C1-10 alkil, C2-6 alkenil i C2-6 alkinil, pri čemu je navedeni C1-10 alkil, C2-6 alkenil ili C2-6 alkinil nesupstituiran ili je opcionalno supstituiran s halogenom ili cijano, ili njihovim kombinacijama; i
R3 se bira iz skupine koju čine halogen i cijano.
6. Spoj ili njegova farmaceutski prihvatljiva sol ili njegov solvat, ili farmaceutski pripravak za uporabu prema patentnom zahtjevu 5, naznačen time, da
R1 predstavlja vodik ili metil,
R2 predstavlja etil, propil, 2-metilpropil, butil, 3-metilbutil ili pentil, i
R3 predstavlja fluor ili klor.
7. Spoj ili njegova farmaceutski prihvatljiva sol ili njegov solvat, ili farmaceutski pripravak za uporabu prema patentnom zahtjevu 5, naznačen time, da se spoj bira iz skupine koja se sastoji od:
8-kloro-3-pentil-3,7-dihidro-1H-purin-2,6-dion,
8-kloro-3-butil-3,7-dihidro-1H-purin-2,6-dion,
8-kloro-1-metil-3-butil-3,7-dihidro-1H-purin-2,6-dion,
8-kloro-1-metil-3-pentil-3,7-dihidro-1H-purin-2,6-dion,
8-kloro-3-(3-metilbutil)-3,7-dihidro-1H-purin-2,6-dion,
8-kloro-3-(2-metilpropil)-3,7-dihidro-1H-purin-2,6-dion, i
8-kloro-1-metil-3-(3-metilbutil)-3,7-dihidro-1H-purin-2,6-dion.
8. Spoj ili njegova farmaceutski prihvatljiva sol ili njegov solvat, ili farmaceutski pripravak za uporabu prema patentnom zahtjevu 5, naznačen time, da spoj jest 8-kloro-3-pentil-3,7-dihidro-1H-purin-2,6-dion ili njegov hidrat.
9. Spoj ili njegova farmaceutski prihvatljiva sol ili njegov solvat, ili farmaceutski pripravak za uporabu prema patentnom zahtjevu 4 ili 5, naznačen time, da uratna bolest ili bolest gihta je hiperuricemija, ulozi, upala zglobova, bol ili uratna nefropatija.
10. Spoj ili njegova farmaceutski prihvatljiva sol ili njegov solvat, ili farmaceutski pripravak za uporabu prema patentnom zahtjevu 9, naznačen time, da hiperuricemija obuhvaća primarnu hiperuricemiju i sekundarnu hiperuricemiju.
11. Spoj ili njegova farmaceutski prihvatljiva sol ili njegov solvat, ili farmaceutski pripravak za uporabu prema patentnom zahtjevu 9, naznačen time, da giht obuhvaća primarni giht i sekundarni giht.
12. Spoj ili njegova farmaceutski prihvatljiva sol ili njegov solvat, ili farmaceutski pripravak za uporabu prema patentnom zahtjevu 9, naznačen time, da upala zglobova uključuje akutni gihtični artritis, supkutane tofi i kronični tofi artritis.
13. Spoj ili njegova farmaceutski prihvatljiva sol ili njegov solvat, ili farmaceutski pripravak za uporabu prema patentnom zahtjevu 9, naznačen time, da uratna nefropatija uključuje akutnu uratnu nefropatiju, kroničnu uratnu nefropatiju i uratnu urolitijazu.
14. Spoj, naznačen time, da je predstavljen formulom (I), ili njegova farmaceutski prihvatljiva sol ili njegov solvat, ili farmaceutski pripravak, naznačen time, da sadrži spoj predstavljen formulom (I), ili njegovu farmaceutski prihvatljivu sol ili njegov solvat za uporabu u smanjivanju nivoa mokraćne kiseline u organizmu,
[image]
gdje s R1 bira iz skupine koju čine vodik i C1-4 alkil, pri čemu je navedeni
C1-4 alkil nesupstituiran ili je opcionalno supstituiran s jednim ili više halogena, cijano, CF3 ili njihovim kombinacijama;
R2 se bira iz skupine koju čine C1-10 alkil, C2-6 alkenil i C2-6 alkinil, pri čemu je navedeni C1-10 alkil, C2-6 alkenil ili C2-6 alkinil nesupstituiran ili je opcionalno supstituiran s halogenom ili cijano, ili njihovim kombinacijama; i
R3 se bira iz skupine koju čine halogen i cijano.
15. Spoj ili njegova farmaceutski prihvatljiva sol ili njegov solvat, ili farmaceutski pripravak za uporabu prema patentnom zahtjevu 14, naznačen time, da
R1 predstavlja vodik ili metil,
R2 predstavlja etil, propil, 2-metilpropil, butil, 3-metilbutil ili pentil, i
R3 predstavlja fluor ili klor.
16. Spoj ili njegova farmaceutski prihvatljiva sol ili njegov solvat, ili farmaceutski pripravak za uporabu prema patentnom zahtjevu 14, naznačen time, da se spoj bira iz skupine koja se sastoji od:
8-kloro-3-pentil-3,7-dihidro-1H-purin-2,6-dion,
8-kloro-3-butil-3,7-dihidro-1H-purin-2,6-dion,
8-kloro-1-metil-3-butil-3,7-dihidro-1H-purin-2,6-dion,
8-kloro-1-metil-3-pentil-3,7-dihidro-1H-purin-2,6-dion,
8-kloro-3-(3-metilbutil)-3,7-dihidro-1H-purin-2,6-dion,
8-kloro-3-(2-metilpropil)-3,7-dihidro-1H-purin-2,6-dion, i
8-kloro-1-metil-3-(3-metilbutil)-3,7-dihidro-1H-purin-2,6-dion.
17. Spoj ili njegova farmaceutski prihvatljiva sol ili njegov solvat, ili farmaceutski pripravak za uporabu prema patentnom zahtjevu 14, naznačen time, da spoj jest 8-kloro-3-pentil-3,7-dihidro-1H-purin-2,6-dion ili njegov hidrat.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510048096 | 2015-01-30 | ||
| CN201510080714 | 2015-02-13 | ||
| CN201510079809 | 2015-02-13 | ||
| CN201510216089 | 2015-04-30 | ||
| EP16742632.9A EP3251675B1 (en) | 2015-01-30 | 2016-01-28 | Prevention or treatment of uric acid or gout disease |
| PCT/CN2016/000061 WO2016119570A1 (zh) | 2015-01-30 | 2016-01-28 | 尿酸性或痛风性疾病的预防或治疗 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211007T1 true HRP20211007T1 (hr) | 2021-09-17 |
Family
ID=56542370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211007TT HRP20211007T1 (hr) | 2015-01-30 | 2021-06-26 | Prevencija ili liječenje uratne bolesti ili gihta |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10322132B2 (hr) |
| EP (1) | EP3251675B1 (hr) |
| JP (1) | JP6678685B2 (hr) |
| KR (1) | KR102128810B1 (hr) |
| CN (1) | CN107206002B (hr) |
| AU (1) | AU2016212625B2 (hr) |
| BR (1) | BR112017016065A2 (hr) |
| CA (1) | CA2973746C (hr) |
| CY (1) | CY1124383T1 (hr) |
| DK (1) | DK3251675T3 (hr) |
| EA (1) | EA034139B1 (hr) |
| ES (1) | ES2881872T3 (hr) |
| HK (2) | HK1244434A1 (hr) |
| HR (1) | HRP20211007T1 (hr) |
| HU (1) | HUE054741T2 (hr) |
| IL (1) | IL253726B2 (hr) |
| LT (1) | LT3251675T (hr) |
| MA (1) | MA41431B1 (hr) |
| MX (1) | MX2017009853A (hr) |
| PL (1) | PL3251675T3 (hr) |
| PT (1) | PT3251675T (hr) |
| SG (2) | SG11201705889VA (hr) |
| SI (1) | SI3251675T1 (hr) |
| TW (1) | TWI680761B (hr) |
| WO (1) | WO2016119570A1 (hr) |
| ZA (1) | ZA201704600B (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024179463A1 (zh) * | 2023-02-27 | 2024-09-06 | 珊顿医药科技新加坡公司 | 化合物8-氯-3-戊基-3,7-二氢-1h-嘌呤-2,6-二酮的晶型及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8906792D0 (en) | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
| AU3725893A (en) | 1992-02-21 | 1993-09-13 | Smithkline Beecham Corporation | TNF inhibitors |
| AR015966A1 (es) | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
| US7713982B2 (en) * | 2004-02-14 | 2010-05-11 | Smithkline Beecham Corporation | Xanthines with HM74A receptor activity |
| ES2355325T3 (es) * | 2006-06-23 | 2011-03-24 | Incyte Corporation | Derivados de purinona como agonistas de hm74a. |
| CA2656002A1 (en) * | 2006-06-23 | 2007-12-27 | Incyte Corporation | Purinone derivatives as hm74a agonists |
| WO2010071865A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| US20110136835A1 (en) * | 2009-09-14 | 2011-06-09 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
| WO2011057110A1 (en) | 2009-11-06 | 2011-05-12 | Ruprecht-Karls-Universitat-Heidelberg | Gpr109a agonists for the treatment of cerebral ischemia |
-
2016
- 2016-01-28 EA EA201791714A patent/EA034139B1/ru unknown
- 2016-01-28 AU AU2016212625A patent/AU2016212625B2/en active Active
- 2016-01-28 MX MX2017009853A patent/MX2017009853A/es unknown
- 2016-01-28 MA MA41431A patent/MA41431B1/fr unknown
- 2016-01-28 WO PCT/CN2016/000061 patent/WO2016119570A1/zh active Application Filing
- 2016-01-28 HU HUE16742632A patent/HUE054741T2/hu unknown
- 2016-01-28 DK DK16742632.9T patent/DK3251675T3/da active
- 2016-01-28 PL PL16742632T patent/PL3251675T3/pl unknown
- 2016-01-28 EP EP16742632.9A patent/EP3251675B1/en active Active
- 2016-01-28 CA CA2973746A patent/CA2973746C/en active Active
- 2016-01-28 CN CN201680001581.8A patent/CN107206002B/zh active Active
- 2016-01-28 LT LTEP16742632.9T patent/LT3251675T/lt unknown
- 2016-01-28 JP JP2017558605A patent/JP6678685B2/ja active Active
- 2016-01-28 SG SG11201705889VA patent/SG11201705889VA/en unknown
- 2016-01-28 BR BR112017016065-0A patent/BR112017016065A2/pt not_active Application Discontinuation
- 2016-01-28 SG SG10201907026RA patent/SG10201907026RA/en unknown
- 2016-01-28 SI SI201631264T patent/SI3251675T1/sl unknown
- 2016-01-28 KR KR1020177024392A patent/KR102128810B1/ko active IP Right Grant
- 2016-01-28 US US15/512,412 patent/US10322132B2/en active Active
- 2016-01-28 ES ES16742632T patent/ES2881872T3/es active Active
- 2016-01-28 PT PT167426329T patent/PT3251675T/pt unknown
- 2016-01-29 TW TW105102935A patent/TWI680761B/zh active
-
2017
- 2017-07-07 ZA ZA2017/04600A patent/ZA201704600B/en unknown
- 2017-07-30 IL IL253726A patent/IL253726B2/en unknown
-
2018
- 2018-03-21 HK HK18103914.7A patent/HK1244434A1/zh unknown
- 2018-04-16 HK HK18104884.1A patent/HK1245146A1/zh unknown
-
2021
- 2021-06-22 CY CY20211100551T patent/CY1124383T1/el unknown
- 2021-06-26 HR HRP20211007TT patent/HRP20211007T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200836T1 (hr) | Liječenje bolesti povezanih s imunitetom i upalnih bolesti | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| HRP20191268T1 (hr) | Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk | |
| RU2017114346A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
| FI3692040T3 (fi) | Kemiallisia yhdisteitä | |
| HRP20201949T1 (hr) | 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji | |
| JP2012184234A5 (hr) | ||
| JP2017523225A5 (hr) | ||
| MX2017007748A (es) | Compuestos de heteroarilo anulares fusionados y su uso como inhibidores del receptor de la tirocina cinasa (trk). | |
| RU2017105353A (ru) | Соединения | |
| RS53898B1 (en) | QUINAZOLINE-4 (3H) -ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS | |
| JP2017528503A5 (hr) | ||
| EA201790088A1 (ru) | Ингибиторы syk | |
| WO2014126944A3 (en) | Inhibitors of the renal outer medullary potassium channel | |
| JP2016518337A5 (hr) | ||
| JP2017520613A5 (hr) | ||
| RU2017114352A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
| HRP20131233T1 (hr) | Terapeutski sastav koji obuhvaä†a specifiäśni antagonist receptora endotelina i pde5-inhibitor | |
| BR112015019754A8 (pt) | derivados de 2-((4-amino-3-(3-fluoro-5-hidroxifenil)-1h-pirazolo[3,4-d]pirimidin-1-il)metil)-3-(2-(trifluoro-metil)bezil)quinazolin-4(3h)-ona e seu uso como inibidores de fosfoinositídeo 3-quinase | |
| RU2018110363A (ru) | Усилитель внутриклеточного атф | |
| HRP20191353T1 (hr) | Supstituirani biciklički dihidropirimidinoni i njihova uporaba u svrhu inhibitora aktivnosti neutrofilne elastaze | |
| GEP20207095B (en) | Fused bicyclic heteroaryl derivatives having activity as phd inhibitors | |
| JP2015526455A5 (hr) | ||
| MX2017000635A (es) | Inhibidores del canal de potasio medular externo renal. | |
| HRP20211007T1 (hr) | Prevencija ili liječenje uratne bolesti ili gihta |